by American Society of Hematology
The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.
Language
🇺🇲
Publishing Since
11/9/2019
Email Addresses
1 available
Phone Numbers
0 available
April 17, 2025
<p>In this How I Treat series episode Blood Associate Editor, Dr. Jason Gotlib speaks with Drs. Aaron Gerds, Andreas Reiter, and Claire Harrison. The conversation focuses on the work and contributions of these authors to How I Treat Myeloproliferative Neoplasms, and exciting advances in the treatment and management of MPNs. </p><p><a href="https://ashpublications.org/blood/article/145/16/1707/536654/Introduction-to-a-How-I-Treat-series-on">See the full How I Treat series in volume 145 issue 16 of Blood</a>.</p>
April 17, 2025
<p>In this week's episode we'll learn about the role of autologous transplant for relapsed myeloma. In an updated analysis of the GMMG ReLApsE trial, salvage autologous transplant offered no survival benefit compared to control chemotherapy. These findings may have clinical implications in an era of alternative, and highly effective, treatment options. After that: Response to DDAVP, or desmopressin, in bleeding disorders. This study is the first large scale meta-analysis to assess the response rate to DDAVP in bleeding disorders. Authors provide new insights into determinants of response, which vary according to the disease type. Finally, turning to diffuse large B cell lymphoma. Germinal center B cells depend on the activity of DOT1 and EZH2 to maintain their pro-proliferative identity. New research shows that combined treatment with DOT1L and EZH2 inhibitors has synergistic activity in vitro.</p><p>Featured Articles:</p><ul><li><a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2024027342">Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial</a></li><li><a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2024026804">DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis</a></li><li><a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2024025500">Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphoma</a></li></ul>
April 10, 2025
<p>In this week's episode we’ll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.</p><p>Featured Articles:</p><ul><li><a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2024024818">IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromes</a></li><li><a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2024025884">Targeting cell-surface VISTA expression on allospecific naïve T cells promotes tolerance</a></li><li><a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2024026830">Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial</a></li></ul>
NEJM Group
Sam and Karine
The Hematologist
JAMA Network
Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
Dr. Neil Love
JAMA Network
JAMA Network
Vinay Prasad, MD MPH
Core IM Team
American College of Physicians
The Curbsiders Internal Medicine Podcast
The Curious Clinicians
The Clinical Problem Solvers
Bernard Marini, Anthony Perissinotti, et al.
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.